Drugs / Vindesin
last change Apr 2019 re-read 2 minutes ago

Vindesin

Developed for
acute lymphoblastic leukemia

Trials 0

Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02042690 Comparator Jul 2014 → Feb 2018 acute lymphoblastic leukemia Peking University Completed No outcome recorded
Phase 3 NCT01659099 Background Sep 2012 → Aug 2016 diffuse large B-cell lymphoma The Lymphoma Academic Research Organisation Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Vindesin “Drug:Vindesin 4mg/d,d4,d11, IV,in cycle 2,4,6” NCT02042690
1

NCT01659099

Route Intravenous “Vindesin 4mg/d,d4,d11, IV” NCT02042690